Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

Size: px
Start display at page:

Download "Understanding Root Cause: Pathogenesis of Hepatic Fibrosis"

Transcription

1 10/1/12 Understanding Root Cause: Pathogenesis of Hepatic Fibrosis Hepatitis C Virus Mild inflammation Inflammation Fibrosis Cirrhosis 1

2 10/1/12 Non-alcoholic Fatty Liver Disease Steatosis Steatohepatitis Fibrosis Cirrhosis Fibrotic Liver Diseases Patients Mice HCV, HBV (Post necrotic cirrhosis) Carbon tetrachloride (CCl4) Thioacetamide (TAA) Mouse with humanized liver with hepatitis infection Secondary biliary fibrosis Bile duct ligation Alcoholic liver disease Intragastric ethanol Autoimmune hepatitis Heterologous serum Non-alcoholic steatohepatitis (NASH) Diet induced obesity Choline deficient diet (CDAA) 2

3 10/1/12 J Clin Invest. 115: 209,

4 Hepatic Stellate Cell (HSC) activation in culture quiescent HSC activated HSC ACTIVATION Vit-A autofluorescence ECM a-sma Modifiers of hepatic fibrosis using knock out mice Susceptibility to fibrosis Knock out: Increased Protective IL-6, IL-10 inos Plasminogen Interferon g Adiponectin Telomerase Bcl-xL SOCS1 (+/-) Keratin Decreased Fibrogenic TNFR1, TLR4, CD14 Angiotensin R1a NADPH oxidase TGFb1, Smad3, MMP13 p21 FGF1/2, FGFR4 Leptin, OB-R Dopamine bhydroxylase FasL, Cathepsin B C5 Hepatology 37: 653,

5 Oxidative stress induces liver fibrosis Ethanol/acetaldehyde AngII, Bile salts HCV proteins P450IIE1 Apoptosis ROS Activation Proliferation Activation NAD(P)H-oxidase NAD(P)H-oxidase Fibrosis Examples of kos NADPH oxidase, angiotensin R1a Renin Angiotensin Pathway in HSCs Induces ROS and Hepatic Fibrosis Angiotensinogen Renin Angiotensin-I ACE-inh ARB ACE Angiotensin-II AT1 NADPH oxidase gp91 phox p67 phox p22 phox. p47 phox p O 2 O 2 Ca +2 flux HSC activation ECM production AT2 Hepatic fibrosis 5

6 NOXs in hepatic stellate cells NOX1 Non-phagocytic form of NOX Expressed in VSMCs and fibroblasts Induced by Ang II, Leptin, PDGF NOX2 Classic phagocytic form of NOX Expressed in macrophages Inducible NOX4 Regulated at level of transcription Increased in inflammation and fibrosis Induced by TGFb Liver fibrosis is blocked by NOX 1/4 inhibitor GKT Vehicle NOX1/4 inhibitor WT SOD1mu B Sirius red positive area (%) NI WT SOD1mu * * * C Vehicle NOX1/4 inhibitor SOD1mu oil WT D Vehicle NOX1/4 inhibitor WT SOD1mu WT SOD1mu oil oil oil oil -SMA -actin E collagen 1(I) mrna (fold) 120 * * * NI TIMP-1 mrna (fold) NI TGF- mrna (fold) WT SOD1mu * * * 5 0 NI oil oil oil * * * 6

7 TGF 1 induces liver fibrogenesis Activates HSCs Stimulates synthesis of ECM Collagens Glycoproteins Proteoglycans Inhibits ECM degradation Inhibits MMPs Stimulates protease inhibitors Increases TGF 1 mrna Examples of ko mice TGFb1, Smad3, MMP13,TLR4 Integrin αvβ6 activates TGFβ TGFb RDG LTBP1 b6 RDG a v TGFbR Sheppard D. Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev Sep;24(3):

8 10/1/12 Hepatocyte apoptosis induces hepatic fibrosis Kupffer cell Phagocytosis Apoptosis MIP-2 KC TGFb1 HSC Apoptotic bodies Hepatocyte Activated HSC F I B R O S I S Hepatocyte Examples of ko mice Fas, Cathepsin B, Bcl-xL, IKKb TLR4-mutant mice display strongly reduced fibrosis after BDL!SMA-staining BDL TLR4WT Sham BDL Sham BDL TLR4mutant Sham BDL Sirius red pos-area (%) Sirius red staining Sham TLR4mutant Hydroxyproline (mg/g liver) TLR4WT 20 Sirius red sham BDL Hydroxyproline sham BDL TLR4WT TLR4mutant 8

9 LPS activates TLR4 to induce fibrosis LPS TGFb-RI TLR4 TGF Chemokines Bambi quiescent HSC Adhesion molecules Kupffer cell HSC activation Collagen deposition Liver fibrosis Studies of modifier genes in patients Modifier genes: Genes that alters the expression of other gene(s) and affects phenotype. Genetic polymorphisms: Stable variations in DNA that are observed in 1% or more of the population (i.e. SNPs). Association studies: epidemiological studies assessing the role of genetic polymorphisms in disease susceptibility and/or progression. 9

10 Modifiers of hepatic fibrosis in patients HCV HFE, Angiotensinogen, TGFb1, CTLA-4, MnSOD, TNFa, IL10, MTP, MCPI/Z, MMP 1/3/9, RANYES, Kertin 8/18, a AT, C5, DDX5, CPT-1A, IFN8 ALD HFE, TGFb1, CTLA-4, MnSOD, TNFa, IL10, CD14, GSTMI/T1 NASH HFE, Angiotensinogen, TGFb1, MnSOD, TNFa, MTP Problems: Inadequate sample size, different populations, statistical stringency, small genetic effects blue genes that modify multiple liver diseases Hepatology 37:653, 2003 Celera Whole Genome Scan for Cirrhosis in HCV Gastro, 2006 Hepatology,

11 Modifier Genes of Hepatic Fibrosis in HCV (Celera, Hepatol. 2008) Predictors Gene (Chr) Risk of genotype or phenotype Frequency (Caucasian Patients) SNP1b SNP2 SNP3 SNP4 SNP5 SNP6 SNF7 Sex Age Alcohol AZIN1 (Chr 8) TLR4 (Chr 9) TRPM5 (Chr 11) None (Chr 15) None (Chr 1) None (Chr 3) AQP2 (Chr 12) GG CC CT, CC AG, AA GG AG, AA GG Male Older 50 g/day 86.9% 87.3% 63.6% 41.6% 72.3% 18.5% 66.7% 69.3% N/A 32.9% Chronic Inflammation leads to fibrosis WBC recruitment INJURY LPS TLR4 Kupffer cell activation TNF- IL-1 MIP-1 HSC activation Activated Myofibroblast TGF-b Ang II Leptin ROS FIBROSIS Ko mice TNF-, TLR4, CD14, LBP 11

12 Reversal of CC1 4 -induced Hepatic Fibrosis Collagen Activated HSCs CC1 4 Post 7d Iredale, JCI 102:538, 1998 Fibrosis and Resolution Fibrosis Resolution ECMs Collagenase TIMPs Activated HSCs 12

13 10/1/12 Removing known stimuli of fibrogenesis reverses fibrosis in patients Inflammation autoimmune hepatitis Ethanol alcoholic liver disease Copper Wilson s disease Iron hemochromatosis Schistosomes schistosomiasis Biliary Obstruction 2ndary biliary cirrhosis Hepatitis B and C viral hepatitis NASH obesity, diabetes Lamivudine decreases activated HSCs a smooth muscle actin staining Pre-LAM Post-LAM J Hepatol 35:749,

14 Rates of Regression of HCV cirrhosis with SVR D Ambrosio et al. Hepatology. Volume 56, pages 532, 2012 Gastric Bypass Surgery Decreased hepatic fibrogenesis in NAFLD Decreased steatosis Decreased activated hepatic stellate cells Pre-GBS Decreased mrnas for intermediate biomarkers of fibrosis: collagen α1(i), TGFβ1, TIMP-1, and αsma Post-GBS 14

15 Chronic Liver Injury Pathogenesis of Hepatic Fibrosis Apoptosis Quiescent HSC Angiotensin PDGF Leptin Fibroblast Fibrogenesis NADPH oxidase Fibrocyte ROS TGFb1 Proliferation SMA+ Myofibroblast 15

Molecular mechanisms of Fibrosis: Targets of Therapy. John P Iredale University of Edinburgh, UK

Molecular mechanisms of Fibrosis: Targets of Therapy. John P Iredale University of Edinburgh, UK Molecular mechanisms of Fibrosis: Targets of Therapy John P Iredale University of Edinburgh, UK Take home messages: The wound healing MFBs of the liver and the hepatic macrophages are key players in progressive

More information

Fibrosis is a highly conserved response to hepatic

Fibrosis is a highly conserved response to hepatic NEW HORIZONS Hepatic Inflammation and Fibrosis: Functional Links and Key Pathways Ekihiro Seki 1,2 and Robert F. Schwabe 3,4 Inflammation is one of the most characteristic features of chronic liver disease

More information

Laura Smart 9/22/2011

Laura Smart 9/22/2011 Laura Smart 9/22/2011 Fibrosis is a wound healing response in which damaged regions are encapsulated by an extracellular matrix or scar. Fibrosis develops in almost all patients with chronic liver injury

More information

NASH Bench to Bedside

NASH Bench to Bedside NASH Bench to Bedside October 2006 Anna Mae Diehl, M.D. Gastroenterology Division Duke University NonAlcoholic Fatty Liver Disease Common ~1/4-1/3 1/3 US adults Outcome highly variable Course indolent

More information

The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease. Ekihiro Seki, M.D.,Ph.D. University of California San Diego

The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease. Ekihiro Seki, M.D.,Ph.D. University of California San Diego The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease Ekihiro Seki, M.D.,Ph.D. University of California San Diego - A manufactured chemical. - Does not exist naturally. Carbon tetrachloride

More information

Figure S1. IRF5 mrna expression is not expressed modulated by steatosis grade in

Figure S1. IRF5 mrna expression is not expressed modulated by steatosis grade in 9-INS-RG-TR- SUPPLEMENTRY MTERILS B IRF mrn expression 1 Control Fatty liver NSH HCV αsm IRF 1 ERG IRF < -33 33- Steatosis (%) < Figure S1. IRF mrn expression is not expressed modulated by steatosis grade

More information

contributes to reversal of biliary fibrosis by Popov et al.

contributes to reversal of biliary fibrosis by Popov et al. Supplementary data to MS Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of biliary fibrosis by Popov et al. Supplementary table 1. Primers and probes used in quantitative

More information

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging

Role of Liver Biopsy. Role of Liver Biopsy 9/3/2009. Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging Liver Biopsies in Viral Hepatitis: Beyond Grading and Staging for further reference: Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach Neil Theise, MD. Depts of Pathology

More information

Mechanisms of hepatic fibrogenesis in chronic liver disease

Mechanisms of hepatic fibrogenesis in chronic liver disease Mechanisms of hepatic fibrogenesis in chronic liver disease JPEMS 2014, Physiopathology Module Corentin Bessy (Nantes) _ Gabrielle Cepella (Amsterdam) _ Charly Gaisne (Angers) _ Gwladys Guilloineau (Angers)

More information

Study Design to Validate Biomarkers of Therapeutic Response in NASH Due to Cirrhosis

Study Design to Validate Biomarkers of Therapeutic Response in NASH Due to Cirrhosis Study Design to Validate Biomarkers of Therapeutic Response in NASH Due to Cirrhosis Detlef Schuppan Institute of Translational Immunology and Research Center for Immune Therapy, University Medical Center

More information

Nottingham Patterns of liver fibrosis and their clinical significance

Nottingham Patterns of liver fibrosis and their clinical significance Nottingham 2006 Patterns of liver fibrosis and their clinical significance Alastair D Burt Professor of Pathology and Dean of Clinical Medicine University of Newcastle upon Tyne Collapse of reticulin

More information

Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease

Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease Advances in Understanding Hepatic Fibrosis and Chronic Liver Disease Scott Friedman, M.D. Fishberg Professor of Medicine Dean for Therapeutic Discovery Chief, Division of Liver Diseases Icahn School of

More information

Supplementary Figure 1. Expression of CUGBP1 in non-parenchymal liver cells treated with TGF-β

Supplementary Figure 1. Expression of CUGBP1 in non-parenchymal liver cells treated with TGF-β Supplementary Figures Supplementary Figure 1. Expression of CUGBP1 in non-parenchymal liver cells treated with TGF-β and LPS. Non-parenchymal liver cells were isolated and treated with or without TGF-β

More information

Reviewers' comments: Reviewer #1 (Remarks to the Author):

Reviewers' comments: Reviewer #1 (Remarks to the Author): Reviewers' comments: Reviewer #1 (Remarks to the Author): The manuscript by Wu et al describes critical role of RNA binding protein CUGBP1 in the development of TGF-beta-mediated liver fibrosis. The activation

More information

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF

WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF WHAT THE EXPERIMENTAL MODELS CAN TEACH US IN NAFLD/NASH? Claudio Tiribelli, MD PhD Scientific Director FIF ctliver@fegato.it Worldwide estimated prevalence of NAFLD distribution of PNPLA3 genotypes 2017-Younussi

More information

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1 Supplemental Tables Supplemental Table 1 Various etiologies of liver cirrhosis and their association with liver stiffness and AST/ALT ratio Disease category Cause Example LS AST/ALT Inflammatory liver

More information

Liver fibrosis: Twenty years after. Fabio Marra Dipartimento di Medicina Sperimentale e Clinica Università di Firenze

Liver fibrosis: Twenty years after. Fabio Marra Dipartimento di Medicina Sperimentale e Clinica Università di Firenze Liver fibrosis: Twenty years after Fabio Marra Dipartimento di Medicina Sperimentale e Clinica Università di Firenze fabio.marra@unifi.it DISCLOSURES: Grants from: ViiV Healthcare Consultant for: Bayer

More information

Bile Acids and Liver Fibrosis Causative Agent and Therapeutic Tool

Bile Acids and Liver Fibrosis Causative Agent and Therapeutic Tool Bile Acids and Liver Fibrosis Causative Agent and Therapeutic Tool Peter Fickert, Andrea Fuchsbichler, Tarek Moustafa, Gernot Zollner, Emina Halilbasic, Ulrike Stöger, Cord Langner, Helmut Denk, and Michael

More information

Alcoholic hepatitis is a drug-induced disorder

Alcoholic hepatitis is a drug-induced disorder Alcoholic hepatitis is a drug-induced disorder Gyongyi Szabo, MD, PhD Professor of Medicine University of Massachusetts Medical School Source: 2 Sobernation.com Clinical Progression of ALD Mortality Acute

More information

Reversal of liver cirrhosis: current evidence and expectations

Reversal of liver cirrhosis: current evidence and expectations REVIEW Korean J Intern Med 2017;32:213-228 https://doi.org/10.3904/kjim.2016.268 Reversal of liver cirrhosis: current evidence and expectations Young Kul Jung and Hyung Joon Yim Division of Gastroenterology

More information

Postn MCM Smad2 fl/fl Postn MCM Smad3 fl/fl Postn MCM Smad2/3 fl/fl. Postn MCM. Tgfbr1/2 fl/fl TAC

Postn MCM Smad2 fl/fl Postn MCM Smad3 fl/fl Postn MCM Smad2/3 fl/fl. Postn MCM. Tgfbr1/2 fl/fl TAC A Smad2 fl/fl Smad3 fl/fl Smad2/3 fl/fl Tgfbr1/2 fl/fl 1. mm B Tcf21 MCM Tcf21 MCM Smad3 fl/fl Tcf21 MCM Smad2/3 fl/fl Tcf21 MCM Tgfbr1/2 fl/fl αmhc MCM C 1. mm 1. mm D Smad2 fl/fl Smad3 fl/fl Smad2/3

More information

Tissue repair. (3&4 of 4)

Tissue repair. (3&4 of 4) Tissue repair (3&4 of 4) What will we discuss today: Regeneration in tissue repair Scar formation Cutaneous wound healing Pathologic aspects of repair Regeneration in tissue repair Labile tissues rapid

More information

MARK AARON BARNES, JR. Submitted in partial fulfillment of the requirements. For the degree Doctor of Philosophy

MARK AARON BARNES, JR. Submitted in partial fulfillment of the requirements. For the degree Doctor of Philosophy MACROPHAGE MIGRATION INHIBITORY FACTOR AND LIVER DISEASE: THE ROLE OF MIF IN ALCOHOL-INDUCED LIVER INJURY AND CARBON TETRACHLORIDE (CCI 4 )-INDUCED LIVER FIBROSIS by MARK AARON BARNES, JR Submitted in

More information

Stimulating healthy tissue regeneration by targeting the 5-HT 2B receptor in chronic liver disease.

Stimulating healthy tissue regeneration by targeting the 5-HT 2B receptor in chronic liver disease. Stimulating healthy tissue regeneration by targeting the 5-HT 2B receptor in chronic liver disease. Mohammad R Ebrahimkhani, Fiona Oakley, Lindsay B Murphy, Jelena Mann, Anna Moles, Maria J Perugorria,

More information

Obstructive nephropathy: Insights from genetically engineered animals

Obstructive nephropathy: Insights from genetically engineered animals Kidney International, Vol. 68 (2005), pp. 925 937 Obstructive nephropathy: Insights from genetically engineered animals JEAN-LOUP BASCANDS and JOOST P. SCHANSTRA Inserm U388, Institut Louis Bugnard, Touluse

More information

Forward-looking Statements

Forward-looking Statements NASDAQ:CNAT Forward-looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements

More information

Detection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection

Detection and significance of PD-1.3 SNP (rs ) and IL28B SNP (rs ) in patients with current or past hepatitis B virus (HBV) infection Detection and significance of PD-1.3 SNP (rs11568821) and IL28B SNP (rs12979860) in patients with current or past hepatitis B virus (HBV) infection Asterios Saitis 1, Nikolaos K. Gatselis 1, Kalliopi Azariadi

More information

Conflicts of Interest in the last 12 months

Conflicts of Interest in the last 12 months STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last

More information

Mark D Gorrell Sumaiya Chowdhury, Fiona Keane, Stephen Twigg, Geoff McCaughan

Mark D Gorrell Sumaiya Chowdhury, Fiona Keane, Stephen Twigg, Geoff McCaughan The protease fibroblast activation protein [FAP] as a biomarker and therapeutic target in chronic liver injury Mark D Gorrell Sumaiya Chowdhury, Fiona Keane, Stephen Twigg, Geoff McCaughan A.W. Morrow

More information

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.

Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem

More information

The Role of Innate Immunity in Alcoholic Liver Disease

The Role of Innate Immunity in Alcoholic Liver Disease ALCOHOL RESEARCH: Current Reviews The Role of Innate Immunity in ic Liver Disease Laura E. Nagy, Ph.D. Laura E. Nagy, Ph.D., is a professor of molecular medicine at Case Western Reserve University School

More information

HepaRG LX2. HepaRG HepaRG LX2 LX2

HepaRG LX2. HepaRG HepaRG LX2 LX2 C Supporting Figure 1. Experimental design of s between and cells. (A) -hepatocytes were isolated from a 30 days of -progenitors. Differentiation into mature hepatocytes was achieved following a 2-weeks

More information

Supplementary Figure 1: Lgr5 expression in liver was induced by CCL4 and decreased after liver recovery. Mice were treated with single dose of CCL4

Supplementary Figure 1: Lgr5 expression in liver was induced by CCL4 and decreased after liver recovery. Mice were treated with single dose of CCL4 Supplementary Figure 1: Lgr5 expression in liver was induced by CCL4 and decreased after liver recovery. Mice were treated with single dose of CCL4 or control oil, the livers were collected at various

More information

Antifibrotic therapy: between hopes and reality. Fabio Marra Dipartimento di Medicina Sperimentale e Clinica University of Florence, Italy

Antifibrotic therapy: between hopes and reality. Fabio Marra Dipartimento di Medicina Sperimentale e Clinica University of Florence, Italy Antifibrotic therapy: between hopes and reality Fabio Marra Dipartimento di Medicina Sperimentale e Clinica University of Florence, Italy Disclosures Abbvie: consultant fees AstraZeneca: consultant fees

More information

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif

Non alcoholic fatty liver and Non alcoholic Steatohepatitis. By Dr. Seham Seif Non alcoholic fatty liver and Non alcoholic Steatohepatitis By Dr. Seham Seif Definition NAFL describe a common clinicopathological conditions characterized by significant lipid deposition in the hepatocytes

More information

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?

1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize? 1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal

More information

Liver Fibrosis: Which Mechanisms Matter?

Liver Fibrosis: Which Mechanisms Matter? REVIEW Liver Fibrosis: Which Mechanisms Matter? Ralf Weiskirchen, Ph.D.,* and Frank Tacke, M.D., Ph.D. HEPATIC FIBROSIS Historically, fibrosis was defined by a World Health Organization expert group in

More information

METABOLIC SYNDROME AND HCV: FROM HCV

METABOLIC SYNDROME AND HCV: FROM HCV METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,

More information

Supplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with

Supplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with Supplementary Figure 1. Repression of hepcidin expression in the liver of mice treated with DMN Immunohistochemistry for hepcidin and H&E staining (left). qrt-pcr assays for hepcidin in the liver (right).

More information

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications

1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the

More information

-sheet 3. -Waseem Alhaj. Maha Shomaf

-sheet 3. -Waseem Alhaj. Maha Shomaf -sheet 3 -Basheer egbaria -Waseem Alhaj Maha Shomaf 1 P a g e Viral hepatitis have many types each type is associated with different outcomes complication, some can result in acute one,others result in

More information

Abhd2 regulates alveolar type Ⅱ apoptosis and airway smooth muscle remodeling: a key target of COPD research

Abhd2 regulates alveolar type Ⅱ apoptosis and airway smooth muscle remodeling: a key target of COPD research Abhd2 regulates alveolar type Ⅱ apoptosis and airway smooth muscle remodeling: a key target of COPD research Shoude Jin Harbin Medical University, China Background COPD ------ a silent killer Insidious,

More information

Scleroderma. Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis

Scleroderma. Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis Scleroderma Chronic multisystemic disease characterized by vasculopathy, variable degree of inflammation, and fibrosis Incidence 3.7-22.8 cases/million Female:male 5:1 Pulmonary fibrosis common, severe

More information

Steatosi epatica ed HCV

Steatosi epatica ed HCV Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

Uncovering the mechanisms of wound healing and fibrosis

Uncovering the mechanisms of wound healing and fibrosis Any Questions??? Ask now or contact support support@sabiosciences.com 1-888-503-3187 International customers: SABio@Qiagen.com Uncovering the mechanisms of wound healing and fibrosis Webinar related questions:

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk @robdgol FATTY LIVER DISEASE Brunt

More information

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA

IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA UNIGASTRO Il fegato come centrale metabolica e i fattori di danno oltre ai virus epatitici IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA Dr Elisabetta Bugianesi Divisione di Gastro-Epatologia

More information

Mesenchymal progenitor cells in intramuscular connective tissue development

Mesenchymal progenitor cells in intramuscular connective tissue development Mesenchymal progenitor cells in intramuscular connective tissue development Min Du, Ph.D. Professor and Endowed Chair Department of Animal Sciences Washington State University Pullman, WA Beef Quality:

More information

Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis

Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis Yukinori Koyama,, David A. Brenner, Tatiana Kisseleva J Clin Invest. 2017;127(4):1254-1270. https://doi.org/10.1172/jci88845.

More information

Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression

Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression University of Windsor Scholarship at UWindsor UWill Discover Undergraduate Conference UWill Discover 2016 Mar 29th, 4:00 PM - 5:00 PM Exploring a Link Between Spy1 and Hepatocellular Carcinoma Progression

More information

Regulator of G-protein signaling 5 is expressed in hepatic stellate cells. and moderates the fibrotic response to injury. Arya J.

Regulator of G-protein signaling 5 is expressed in hepatic stellate cells. and moderates the fibrotic response to injury. Arya J. Regulator of G-protein signaling 5 is expressed in hepatic stellate cells and moderates the fibrotic response to injury Arya J. Bahrami A dissertation submitted in partial fulfillment of the requirements

More information

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic

Update on Nonalcoholic Fatty Liver Disease. Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Update on Nonalcoholic Fatty Liver Disease Kathleen E Corey, MD, MPH, MMSc Director, Mass General Fatty Liver Clinic Outline Defining the phenotypes of nonalcoholic fatty liver disease NAFLD Diagnostics

More information

Novel function of NADPH oxidase in atherosclerosis. Yun Soo Bae Department of Life Science Ewha Womans University

Novel function of NADPH oxidase in atherosclerosis. Yun Soo Bae Department of Life Science Ewha Womans University Novel function of NADPH oxidase in atherosclerosis Yun Soo Bae Department of Life Science Ewha Womans University Recent understanding of ROS: act as second messengers e e Catalase/peroxidase O 2 H 2 O

More information

Connective Tissue Response in IBD

Connective Tissue Response in IBD Connective Tissue Response in IBD Dr I C Lawrance MB BS, PhD FRACP School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital Intestinal response to Chronic Inflammation Control

More information

* Author to whom correspondence should be addressed; Tel.: ; Fax:

* Author to whom correspondence should be addressed;   Tel.: ; Fax: Cancers 2014, 6, 1220-1255; doi:10.3390/cancers6031220 Review OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Fibrogenesis and Carcinogenesis in Nonalcoholic Steatohepatitis (NASH): Involvement

More information

Apoptosis in chronic hepatitis C

Apoptosis in chronic hepatitis C Apoptosis in chronic hepatitis C Dr med. Anna Parfieniuk-Kowerda Department of Infectious Diseases and Hepatology Medical University of Bialystok Poland APOPTOSIS Apoptosis - type I programmed cell death

More information

The role of Hepatitis C Virus in hepatocarcinogenesis

The role of Hepatitis C Virus in hepatocarcinogenesis The role of Hepatitis C Virus in hepatocarcinogenesis Laura Beretta Fred Hutchinson Cancer Research Center l8 Incidence and mortality of the five most common cancers worldwide, 2000 Incidence Lung Breast

More information

Role of Inflammation in Pulmonary Hypertension

Role of Inflammation in Pulmonary Hypertension Role of Inflammation in Pulmonary Hypertension K. R. Stenmark University of Colorado Denver, USA Prominent Fibroproliferative Changes are Observed in the Lung Vasculature of Infants With Pulmonary Arterial

More information

MSC-derived exosomes: a novel possible treatment for liver fibrosis

MSC-derived exosomes: a novel possible treatment for liver fibrosis MSC-derived exosomes: a novel possible treatment for liver fibrosis Essay Lotte Dietz Supervised by Marco Harmsen S2250853 Master Biology, Neuro- and behavioural track (started sept 2014) December 2016

More information

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1 A B mir-141, human cell lines mir-2c, human cell lines mir-141, hepatocytes mir-2c, hepatocytes Relative RNA.1.8.6.4.2 Relative RNA.3.2.1 Relative RNA 1.5 1..5 Relative RNA 2. 1.5

More information

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin Know Differences and Provide Examples Chapter * Innate Immunity * kin and Epithelial Barriers * Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive

More information

INFLAMMATION & REPAIR

INFLAMMATION & REPAIR INFLAMMATION & REPAIR Lecture 7 Chemical Mediators of Inflammation Winter 2013 Chelsea Martin Special thanks to Drs. Hanna and Forzan Course Outline i. Inflammation: Introduction and generalities (lecture

More information

University of Groningen

University of Groningen University of Groningen Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice de Meijer, Vincent E.; Sverdlov, Deanna

More information

ΦΛΕΓΜΟΝΗ ΚΑΙ ΔΙΑΒΗΤΗΣ

ΦΛΕΓΜΟΝΗ ΚΑΙ ΔΙΑΒΗΤΗΣ ΦΛΕΓΜΟΝΗ ΚΑΙ ΔΙΑΒΗΤΗΣ ΘΩΜΑΣ ΠΑΠΑΔΟΠΟΥΛΟΣ, MD, PHD ΕΠΕΜΒΑΤΙΚΟΣ ΚΑΡΔΙΟΛΟΓΟΣ ΙΑΤΡΙΚΟ ΔΙΑΒΑΛΚΑΝΙΚΟ ΚΕΝΤΡΟ Inflammation as a cause of disease has entered the popular imagination. Diet ( macronutrients )

More information

Expression of MMPs and TIMPs in liver fibrosis a systematic review with special emphasis on anti-fibrotic strategies

Expression of MMPs and TIMPs in liver fibrosis a systematic review with special emphasis on anti-fibrotic strategies Journal of Hepatology 46 (2007) 955 975 Special article Expression of MMPs and TIMPs in liver fibrosis a systematic review with special emphasis on anti-fibrotic strategies Stefanie Hemmann 1,Jürgen Graf

More information

Available online at

Available online at Available online at www.annclinlabsci.org Annals of Clinical & Laboratory Science, vol. 45, no. 6, 2015 669 Galectin-3 Concentration in Liver Diseases Monika Gudowska 1, Ewa Gruszewska 1, Bogdan Cylwik

More information

Mario Strazzabosco MD, PhD

Mario Strazzabosco MD, PhD Mario Strazzabosco MD, PhD Professor of Medicine & Gastroenterology Deputy Director, Yale Liver Center, Director, Hepatobiliary Cancer Program Yale University School of Medicine Director Master Program

More information

How Will New Therapies Affect HCC Development?

How Will New Therapies Affect HCC Development? How Will New Therapies Affect HCC Development? July 6, 2018 Scott Friedman, M.D. Fishberg Professor of Medicine Dean for Therapeutic Discovery Chief, Division of Liver Diseases Icahn School of Medicine

More information

Understanding your FibroScan Results

Understanding your FibroScan Results PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your

More information

Liver fibrosis is the end result of chronic liver injury of

Liver fibrosis is the end result of chronic liver injury of GASTROENTEROLOGY 2010;139:1375 1384 Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 Plays a Key Role in Stellate Cell Activation and Liver Fibrogenesis In Vivo JOY X. JIANG,* SENTHIL VENUGOPAL,

More information

Innate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin

Innate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin Chapter Know Differences and Provide Examples Innate Immunity kin and Epithelial Barriers Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive Immunity

More information

Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9

Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S100A9 Abnormally differentiating keratinocytes in the epidermis of systemic sclerosis patients show enhanced secretion of CCN2 and S1A9 Joanna Nikitorowicz-Buniak UCL Division of Medicine Systemic sclerosis

More information

The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease

The Role of Chemokines in Hepatitis C Virus-Mediated Liver Disease Int. J. Mol. Sci. 2014, 15, 4747-4779; doi:10.3390/ijms15034747 Review OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms The Role of Chemokines in Hepatitis

More information

Improving the Lives of Patients with Liver Diseases

Improving the Lives of Patients with Liver Diseases Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and

More information

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic

More information

Supplementary Figure 1 ITGB1 and ITGA11 increase with evidence for heterodimers following HSC activation. (a) Time course of rat HSC activation

Supplementary Figure 1 ITGB1 and ITGA11 increase with evidence for heterodimers following HSC activation. (a) Time course of rat HSC activation Supplementary Figure 1 ITGB1 and ITGA11 increase with evidence for heterodimers following HSC activation. (a) Time course of rat HSC activation indicated by the detection of -SMA and COL1 (log scale).

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

Liver Disease NASH/Fibrosis Model

Liver Disease NASH/Fibrosis Model Liver Disease NASH/Fibrosis Model Please contact: Dipti Deshpande PhD ddeshpande@woodlandpharma.com or Carol Gebert PhD cgebert@woodlandbiosciences.com 617-513-5280 Liver Diseases Comprise a Growing Market

More information

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006 Vt-2006 The pathology of the liver, bile ducts and pancreas Richard Palmqvist Docent, ST-läkare, Klin Pat Lab, Labcentrum The lecture in summary Introduction, histology & physiology in brief General phenomenon

More information

Screening cardiac patients for advanced liver disease

Screening cardiac patients for advanced liver disease HKASLD 30 th ASM and International Symposium on Hepatology 2017 Screening cardiac patients for advanced liver disease 5 Nov 2017 Dr. Lau Yue Leung Joulen Pamela Youde Nethersole Eastern Hospital NAFLD

More information

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly

More information

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need? Rob Goldin r.goldin@imperial.ac.uk Fatty liver disease Is there fatty

More information

CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT. Background and Significance

CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT. Background and Significance CHAPTER V LOSS OF HISTONE DEACETYLASE 3 INCREASES SUSCEPTIBILITY FOR GENOMIC DAMAGE AND DISEASE DEVELOPMENT Background and Significance The metabolic syndrome (MetS) is defined in an individual who has

More information

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy Goals Share an interesting case Important because it highlights a common problem that we re likely to

More information

Bile acids initiate cholestatic liver injury by triggering a hepatic specific inflammatory response. Supplementary Results

Bile acids initiate cholestatic liver injury by triggering a hepatic specific inflammatory response. Supplementary Results Bile acids initiate cholestatic liver injury by triggering a hepatic specific inflammatory response Shi-Ying Cai 1, Xinshou Ouyang 1, Yonglin Chen 1, Carol J. Soroka 1, Juxian Wang 2, Albert Mennone 1,

More information

shehab Moh Tarek ... ManarHajeer

shehab Moh Tarek ... ManarHajeer 3 shehab Moh Tarek... ManarHajeer In the previous lecture we discussed the accumulation of oxygen- derived free radicals as a mechanism of cell injury, we covered their production and their pathologic

More information

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical

Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Nonalcoholic Fatty Liver Disease in Children: Typical and Atypical Disclosure Naim Alkhouri, MD discloses the following relationships with commercial companies: Membership in the Speakers Bureau for Alexion

More information

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University

The Effect of Antiviral Therapy on Liver Fibrosis in CHC. Jidong Jia Beijing Friendship Hospital, Capital Medical University The Effect of Antiviral Therapy on Liver Fibrosis in CHC Jidong Jia Beijing Friendship Hospital, Capital Medical University 2016-5-29 1 Disclosure Consultation for Abbvie, BMS, Gilead, MSD, Novartis and

More information

Clinical Trials & Endpoints in NASH Cirrhosis

Clinical Trials & Endpoints in NASH Cirrhosis Clinical Trials & Endpoints in NASH Cirrhosis April 25, 2018 Peter G. Traber, MD CEO & CMO, Galectin Therapeutics 2018 Galectin Therapeutics NASDAQ: GALT For more information, see galectintherapeutics.com

More information

Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats

Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats Guo MZ et al / Acta Pharmacol Sin 2002 Aug; 23 (8): 739-744 739 2002, Acta Pharmacologica Sinica ISSN 1671-4083 Shanghai Institute of Materia Medica Chinese Academy of Sciences http://www.chinaphar.com

More information

Macrophage derived Wnt signalling opposes Notch signalling in a Numb mediated manner to specify HPC fate in chronic liver disease in human and mouse.

Macrophage derived Wnt signalling opposes Notch signalling in a Numb mediated manner to specify HPC fate in chronic liver disease in human and mouse. Macrophage derived Wnt signalling opposes Notch signalling in a Numb mediated manner to specify HPC fate in chronic liver disease in human and mouse. Luke Boulter, Olivier Govaere, Tom G Bird, Sorina Radulescu,

More information

Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ

Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ Review series Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ John P. Iredale Medical Research Council/University of Edinburgh Centre for Inflammation

More information

Subject Index. Bcl-2, apoptosis regulation Bone marrow, polymorphonuclear neutrophil release 24, 26

Subject Index. Bcl-2, apoptosis regulation Bone marrow, polymorphonuclear neutrophil release 24, 26 Subject Index A1, apoptosis regulation 217, 218 Adaptive immunity, polymorphonuclear neutrophil role 31 33 Angiogenesis cancer 178 endometrium remodeling 172 HIV Tat induction mechanism 176 inflammatory

More information

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College

New insights into fatty liver disease. Rob Goldin Centre for Pathology, Imperial College New insights into fatty liver disease Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Prevalence of NASH Global prevalence of NAFLD is 25% with highest prevalence in the Middle

More information

Original Article mir-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic liver

Original Article mir-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic liver Int J Clin Exp Pathol 2015;8(4):3994-4000 www.ijcep.com /ISSN:1936-2625/IJCEP0006145 Original Article mir-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic

More information

Therapeutic targets and the management of NASH

Therapeutic targets and the management of NASH Therapeutic targets and the management of NASH Joo Hyun Sohn, MD. Professor of Medicine, College of Medicine, Hanyang University Division of Gastroenterology and Hepatology Hanyang University Guri Hospital

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

Innate Immune Consequences of Hepatocyte Injury. Katherine J. Brempelis. A dissertation. submitted in partial fulfillment of the

Innate Immune Consequences of Hepatocyte Injury. Katherine J. Brempelis. A dissertation. submitted in partial fulfillment of the Innate Immune Consequences of Hepatocyte Injury Katherine J. Brempelis A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington

More information

Disclosures. Outline. Nothing to disclose. Dysbiosis and the gut barrier. Endotoxemia and the liver. Impact of products of bacterial metabolism

Disclosures. Outline. Nothing to disclose. Dysbiosis and the gut barrier. Endotoxemia and the liver. Impact of products of bacterial metabolism Disclosures Nothing to disclose Outline Dysbiosis and the gut barrier Endotoxemia and the liver Impact of products of bacterial metabolism 1 Dysbiosis in obesity Obesity: Dysbiosis, shown in multiple settings

More information